For Pancreatic ductal adenocarcinoma

Discovery Optimisation Pre-clinical Phase 1 Phase 2

Small molecule, re-formulation and re-purposing of generic risperidone, an anti-psychotic displaying anti-cancer activity when formulated in a specific lipid mixture

Primary indication: Pancreatic ductal adenocarcinoma

Follow-up indications: Any adenocarcinoma type

Licensed from: Tangent Reprofiling Limited, a member of the SEEK group

Published research: Clinical Pharmacokinetics of a Lipid-Based Formulation of Risperidone, VAL401: Analysis of a Single Dose in an Open-Label Trial of Late-Stage Cancer Patients. Suzanne J. Dilly, George S. Morris, Paul C. Taylor, Frederic Parmentier, Coralie Williams, Mohammad Afshar. Eur J Drug Metab Pharmacokinet 2019 (44) 557.

A chemical genomics approach to drug reprofiling in oncology: Antipsychotic drug risperidone as a potential adenocarcinoma treatment. Suzanne J. Dilly, Andrew J. Clark, Andrew Marsh, Daniel A. Mitchell, Colin W.G. Fishwick, Paul C. Taylor, Ricky Cain. Cancer Letters 393 2017 16-21.

Pimping up Drugs Recovered, Superannuated and Under Exploited Drugs - An Introduction to the Basics of Drug Reprofiling: Suzanne J. Dilly, George S. Morris. Curr Drug Discov Technol. 2017 Jun; 14(2): 121–126.

Patents: PCT patent family applications WO/2014/049071; WO/2015/169971.

Granted and allowed patents: AU2013322612; CN104797271; EP2900270; IL62081; JP6434410; JP6734346; MX15003899; NZ706067; NZ726050; US9072743; US9375433; US9585887; US9585890; US9808462; US10111877; further patents pending.